<DOC>
	<DOCNO>NCT02347852</DOCNO>
	<brief_summary>The purpose trial quantitatively assess average amount physical activity patient capable perform receive regorafenib treatment metastatic colorectal cancer . The assessment reference value , measure CE ( Conformité Européene ) -certified pedometer international physical activity questionnaire , allow estimation feasible amount physical activity patient therapeutic setting . This study available patient include global non-interventional study CORRELATE ( Safety efficacy regorafenib metastatic colorectal cancer patient ; NCT01843400 ) Austria .</brief_summary>
	<brief_title>Assessment Physical Activity During Therapy With Regorafenib Metastatic Colorectal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<criteria>Patients diagnose mCRC previously treat , consider candidate , locally approve standard treatment ( ) decision make per investigator 's routine treatment practice prescribe regorafenib . Patients enrol NIS CORRELATE Austria Signed patient inform consent local OS Subjects unwilling complete questionnaire involve local OS Subjects unwilling wear pedometer</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>